Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30190272 | 0.73 | KCNH2 (0.36) | KCNH2LMNAGRIN2B | |
| SCHEMBL24828461 | 0.71 | MAPT (0.34) | KCNH2LMNAGAAPOLB | |
| SCHEMBL24828397 | 0.71 | HDAC3 (0.36) | KCNH2KLKB1KLK1GAA | |
| SCHEMBL24828355 | 0.69 | HDAC6 (0.34) | KCNH2LMNAGAAPOLB | |
| SCHEMBL19889721 | 0.69 | L3MBTL1 (0.37) | KCNH2 | |
| SCHEMBL17673290 | 0.68 | PTGS2 (0.48) | LMNAGAAPOLB | |
| SCHEMBL24828555 | 0.68 | GAA (0.36) | KCNH2GAAPOLB | |
| SCHEMBL24828445 | 0.67 | L3MBTL1 (0.38) | — | |
| SCHEMBL24828446 | 0.66 | MAPT (0.34) | KCNH2LMNA | |
| SCHEMBL17002589 | 0.65 | PDK2 (0.35) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | KCNH2 3333/4885KLKB1 4706/4885KLK1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.